Ok, so I’m going to start by apologizing for my recent absence, but I promise that I had good reason. I have a normal day job. I have to work. I have expenses. I have to pay the bills…. because lets be honest, IFRX isn’t.
As we get into Chapter 4, we discuss valuable assets, and the differences, advantages and disadvantages of being first and second movers. In the world of Biotech, industries continually strive to be a first mover, and utilize the 20 years of patent protection covered by the United States. Millions upon millions are spent every year to develop these new medications because the payout over those two decades more than reimburses the initial investors. That is, if they develop the next best thing. The problem being, is that these wins don’t happen every year. They are not given, they are not guaranteed.
First movers are the companies that make the initial product, develop the technology, the ingredients. Second movers, are the ones that are able to produce this great product, for upwards of half-off, as they try to take advantage of the now-known market. In the industry, Advil, Tylenol, Aleve are the first movers. Generic medications are the second movers. Those that quickly make the product, try to steal profits, while making a suitable product that customers will buy. I personally, am a second mover buyer when it comes to the industry. What are you???
IFRX 